The Corner

Prescription Drugs

Jerry, you seem to want to keep arguing about Bush’s record on entitlements even though your original argument is now far back in the dust. What you don’t account for was that congressional support for an expensive prescription-drug benefit was nearly unanimous — most of the no votes came from Democrats who wanted a bigger benefit. This consensus, meanwhile, reflected 80 percent + public support for the new benefit. Under those circumstances, yes, an expensive new benefit was inevitable.

Ramesh Ponnuru is a senior editor for National Review, a columnist for Bloomberg Opinion, a visiting fellow at the American Enterprise Institute, and a senior fellow at the National Review Institute.

Recommended

The Latest